Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension.
Glucagon-like peptide-1
Headache
Idiopathic intracranial hypertension
Visual worsening
Weight loss
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
18 Jul 2023
18 Jul 2023
Historique:
received:
31
05
2023
accepted:
13
07
2023
medline:
19
7
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
In idiopathic intracranial hypertension (IIH), sustained weight loss is the main pillar in modifying disease course, whereby glucagon-like peptide-1 receptor agonists (GLP-1-RAs) could present an attractive treatment option. In this open-label, single-center, case-control pilot study, patients with IIH (pwIIH) and a body mass index (BMI) of ≥ 30 kg/m We included 39 pwIIH (mean age 33.6 years [SD 8.0], 92.3% female, median BMI 36.3 kg/m This open-label, single-center pilot study suggests that GLP-1-RAs are an effective and safe treatment option for achieving significant weight loss with a favorable effect on headache, leading to reduced acetazolamide dosage in pwIIH.
Sections du résumé
BACKGROUND
BACKGROUND
In idiopathic intracranial hypertension (IIH), sustained weight loss is the main pillar in modifying disease course, whereby glucagon-like peptide-1 receptor agonists (GLP-1-RAs) could present an attractive treatment option.
METHODS
METHODS
In this open-label, single-center, case-control pilot study, patients with IIH (pwIIH) and a body mass index (BMI) of ≥ 30 kg/m
RESULTS
RESULTS
We included 39 pwIIH (mean age 33.6 years [SD 8.0], 92.3% female, median BMI 36.3 kg/m
CONCLUSIONS
CONCLUSIONS
This open-label, single-center pilot study suggests that GLP-1-RAs are an effective and safe treatment option for achieving significant weight loss with a favorable effect on headache, leading to reduced acetazolamide dosage in pwIIH.
Identifiants
pubmed: 37460968
doi: 10.1186/s10194-023-01631-z
pii: 10.1186/s10194-023-01631-z
pmc: PMC10353241
doi:
Substances chimiques
Glucagon-Like Peptide-1 Receptor
0
Acetazolamide
O3FX965V0I
Glucagon-Like Peptide 1
89750-14-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
89Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2012;7(4):e34823
pubmed: 22536333
Neurology. 2013 Sep 24;81(13):1159-65
pubmed: 23966248
Peptides. 1991 Jul-Aug;12(4):861-3
pubmed: 1788147
Ophthalmology. 1991 May;98(5 Suppl):807-22
pubmed: 2062514
J Headache Pain. 2021 Oct 7;22(1):118
pubmed: 34620087
BMJ. 2010 Jul 07;341:c2701
pubmed: 20610512
Brain. 2023 May 2;146(5):1821-1830
pubmed: 36907221
Diabetes Obes Metab. 2022 Jan;24(1):94-105
pubmed: 34514682
J Neuroophthalmol. 2019 Mar;39(1):82-93
pubmed: 30762716
Invest Ophthalmol Vis Sci. 2014 Nov 04;55(12):8173-9
pubmed: 25370513
Neurol Sci. 2020 Dec;41(Suppl 2):417-421
pubmed: 32852682
Endocrine. 2022 Mar;75(3):718-724
pubmed: 34981419
JAMA. 2022 Jan 11;327(2):138-150
pubmed: 35015037
Rev Endocr Metab Disord. 2014 Sep;15(3):181-7
pubmed: 24811133
Front Endocrinol (Lausanne). 2019 Apr 26;10:260
pubmed: 31080438
J Neurol Neurosurg Psychiatry. 1982 Jan;45(1):13-8
pubmed: 7062066
Arch Neurol. 1982 Aug;39(8):461-74
pubmed: 7103794
Diabetes Metab Syndr. 2022 Jun;16(6):102511
pubmed: 35623229
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1088-1100
pubmed: 29903905
Clin Med Insights Endocrinol Diabetes. 2011;4:47-62
pubmed: 22879794
J Headache Pain. 2021 Oct 10;22(1):123
pubmed: 34629054
J Neurol. 2012 May;259(5):886-94
pubmed: 22008872
Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1841-8
pubmed: 23589277
J Neurol. 2023 Feb;270(2):851-863
pubmed: 36242625
Br J Pharmacol. 2022 Feb;179(4):600-624
pubmed: 34519026
Neurology. 2021 Jul 13;97(2):68-79
pubmed: 33910937
Clin Neurol Neurosurg. 2011 Dec;113(10):839-43
pubmed: 21700384
Diabetes. 2014 Dec;63(12):4186-96
pubmed: 25071023
Headache. 2023 May;63(5):601-610
pubmed: 36753388
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3278-81
pubmed: 12882770
J Clin Invest. 2014 Oct;124(10):4223-6
pubmed: 25202976
J Headache Pain. 2021 Jul 8;22(1):67
pubmed: 34238219
Eye (Lond). 2019 Mar;33(3):478-485
pubmed: 30356129
Int J Obes (Lond). 2021 May;45(5):923-933
pubmed: 33462358
Cell Metab. 2018 Apr 3;27(4):740-756
pubmed: 29617641
Eye (Lond). 1988;2 ( Pt 4):358-66
pubmed: 3075564
Diabetes Obes Metab. 2022 Aug;24(8):1553-1564
pubmed: 35441470
JAMA Neurol. 2021 Jun 1;78(6):678-686
pubmed: 33900360
Am J Ophthalmol. 2007 Apr;143(4):635-41
pubmed: 17386271
Br J Ophthalmol. 2012 Mar;96(3):375-9
pubmed: 21653211
Mod Probl Ophthalmol. 1975;14:203-35
pubmed: 170510
Mol Metab. 2019 Dec;30:72-130
pubmed: 31767182
Obes Surg. 2017 Feb;27(2):513-521
pubmed: 27981458
Sci Transl Med. 2017 Aug 23;9(404):
pubmed: 28835515